 |
|
|
|
|
|
|
| |
|
|
|
|
| |
|
|
Gregory
J. Baigent
Vice President, Pulmonary
Transplant Program
Greg Baigent joins APT with over
20 years of experience in pharmaceutical research
and biotechnology. His development career at Cetus
and Chiron Corporation includes a diverse mix of
small molecules, monoclonal antibodies, growth factors,
gene therapies and immune mediators at all stages
of development and resulted in two product launches.
Most recently Greg led Chiron BioPharma’s lead
Phase 3 development program in Severe Community Acquired
Pneumonia patients. His most recent post as Vice
President, Project Management for Peplin, USA, and
his appointment as Vice President, Pulmonary Transplant
Program for APT, are the culmination of a unique,
multidisciplinary career history that includes academia
and industry and spans basic research, regulatory
affairs, marketing, project management and project
leadership. Greg earned his B.Sc. (with honors) in
Microbiology from the University of Kent in Canterbury,
England. |
|
| |
|
|
|
|
| |
|
|
|
|
| |
|
|
|
|
| |
 |
|
Janice
Lee
Senior Director, Project Management
Janice Lee has extensive experience working with small
molecules, vaccines, oncology, gene therapy and drug/device
combinations from early development through commercial
launch and marketed products. She has worked at small
and large companies in positions of increasing responsibility.
Some of Janice’s previous roles include stints
at Genentech, MedImmune, Cell Genesys, Vivus and Chiron/Novartis
in the areas of analytical development, production planning
and project management. She has spent the majority of
her career working on global and/or partnered programs.
Janice earned a Bachelor’s Degree in Biology from
San Francisco State University, followed by a Master
of Public Administration degree from Notre Dame de Namur
University.
|
|
| |
|
|
|
|
| |
|
|
|
|
| |
|
|
Meredith
Brown-Tuttle, RAC
Director, Regulatory
Affairs
Meredith Brown-Tuttle’s fifteen years experience
in biotech incorporates all aspects of drug, device and
biologics development including clinical research, data
management, medical writing, and regulatory affairs.
She has held senior regulatory positions at several Bay
Area biotech companies and a full-service CRO. She has
written and managed numerous drug and biologic submissions
to U.S. and international regulatory agencies, developed
regulatory strategy for both device and drug companies,
and conducted worldwide regulatory intelligence. She
is also the author of the book, “IND Submissions:
A Primer,” published by Barnett. Ms. Brown-Tuttle
graduated with a bachelor’s degree in biological
psychology from San Jose State University.
|
|
| |
|
|
|
|
| |
|
|
|
|
| |
|
|
|
|
| |
|
|
Wendy
Verret
Senior Director, Clinical
Operations
Wendy Verret joined APT as Senior
Director of Clinical Operations in August 2008 and
started working as a consultant to APT in 2007. She
has more than 12 years experience in clinical research
in several therapeutic areas including cardiovascular
disease, oncology, infectious disease, and pulmonary
disease. Previously, Wendy held clinical operations
positions of increasing seniority at Roche, Genentech
and most recently, Novartis (formerly Chiron). Additionally,
she has provided consulting services to biopharmaceutical
companies on strategic development and implementation
of global clinical trials. Wendy earned her Masters
of Public Health in epidemiology from the Mailman
School of Public Health at Columbia University and
is currently a doctoral student in epidemiology at
the University of California, Berkeley. |
|
| |
|
|
|
|
|
|
